CBM C1
Alternative Names: CBM-C1Latest Information Update: 02 Jan 2023
At a glance
- Originator CellionBioMed
- Class Skin disorder therapies
- Mechanism of Action Small-conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Keloids; Scars
Most Recent Events
- 29 Dec 2022 CBM C1 is still in phase I trial for Keloids in South Korea (CellionBioMed pipeline, December 2022)
- 29 Dec 2022 CBM C1 is still in phase I trial for Scars in South Korea (CellionBioMed pipeline, December 2022)
- 22 Jun 2022 CellionBioMed plans a phase II trial for Scars and Keloids, in 2023 (CellionBioMed pipeline, June 2022)